

# Effects of Omega-3 Supplementation on Components of the Endocannabinoid System and Metabolic and Inflammatory Responses in Adipose and Liver of Peripartum Dairy Cows

**Gitit Kra**

Agricultural Research Organization Volcani Center

**Jayasimha Rayalu Daddam**

Agricultural Research Organization Volcani Center

**Uzi Moallem**

Agricultural Research Organization Volcani Center

**Hadar Kamer**

Agricultural Research Organization Volcani Center

**Radka Kočvarová**

Hebrew University School of Pharmacy

**Alina Nemirovski**

Hebrew University School of Pharmacy

**G. Andres Contreras**

Michigan State University

**Joseph Tam**

Hebrew University School of Pharmacy

**Maya Zachut** (✉ [mayak@volcani.agri.gov.il](mailto:mayak@volcani.agri.gov.il))

Agricultural Research Organization Volcani Center <https://orcid.org/0000-0002-9644-6028>

---

## Research Article

**Keywords:** Omega-3, Dairy cows, Endocannabinoid system, Adipose, Liver

**Posted Date:** March 30th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1481439/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Background

Dietary supplementation of omega-3 fatty acids can reduce the activation of the endocannabinoid system (ECS) by decreasing the availability of arachidonic acid, thus lowering endocannabinoids (eCBs) levels. The ECS is a modulator of energy metabolism, stress response and inflammation in mammals, yet there is little information on the roles of the ECS in transition dairy cows. During the periparturient period, the adipose tissue and liver are the main metabolic organs that participate in the adaptations of dairy cows to onset of lactation; however, exceeded adipose tissue lipolysis and accumulation of lipids in the liver have adverse effects on cows' physiology. Here we aimed to examine whether omega-3 supplementation during the transition period will modulate ECS activation and affect metabolic and inflammatory indices in postpartum dairy cows, by supplementing twenty-eight transition Holstein dairy cows with either saturated fat (CTL) or encapsulated flaxseed oil (FLX). Components of the ECS, metabolic and inflammatory markers were measured in blood, liver, and subcutaneous adipose tissue.

## Results

FLX supplementation reduced feed intake ( $P < 0.01$ ) and reduced plasma levels of arachidonic acid ( $P = 0.02$ ) and anandamide ( $P = 0.03$ ) postpartum compared to CTL. The mRNA expression of the cannabinoid receptor 1 (*CNR1/CB1*) tended to be lower in white blood cells of FLX than in CTL ( $P = 0.10$ ), and protein abundance of ECS receptor monoacylglycerol lipase was higher in peripheral blood mononuclear cells of FLX than in CTL ( $P = 0.04$ ). In adipose tissue, palmitoylethanolamide levels were lower in FLX than in CTL ( $P = 0.02$ ), relative mRNA expressions of lipogenic genes were higher, and the protein abundance of cannabinoid receptor 2 ( $P = 0.08$ ) and monoacylglycerol lipase ( $P = 0.10$ ) tended to be higher in FLX compared to CTL. Hepatic 2-arachidonoylglycerol tended to be higher ( $P = 0.07$ ), and interleukin-6 mRNA expression was lower in liver of FLX than in CTL ( $P = 0.03$ ).

## Conclusions

Nutritional supplementation of omega-3 fatty acids seems to modulate ECS activation, which could be related to lower feed intake. The altered ECS components in blood, adipose tissue and liver are associated with moderate modulations in lipid metabolism in the adipose and inflammation in liver of peripartum dairy cows.

## Background

The transition period from late pregnancy to calving and the onset of lactation is a crucial time for dairy cows, and is characterized by several changes in endocrine, metabolic, and immune functions. Within 4 days of lactation, the mammary gland uptake for glucose, amino acids and fatty acids are several folds

more than those of the fetus and utero-placenta before the term of pregnancy [1]; however, the cow's feed intake is limited during this period, which leads to a negative energy balance. When energy supply is limited, fatty acids from the adipose tissue (AT) are used as a source of energy and this initiates lipolysis in the AT [2]. Metabolic adaptations such as lipid mobilization are accompanied by alterations in inflammatory and immune responses and functions [2]. During the peripartum period, cows also experience systemic subacute inflammation, which is accompanied by a mild increase in pro-inflammatory mediators [3]. In most cows, negative energy balance and lipolysis decrease, and AT inflammation resolves as lactation progresses. However, if lipolysis dysregulation occurs and lipolysis rate does not decrease, AT inflammation will become chronic and lead to high disease susceptibility, poor lactation performance, reproductive failure, and may lead to increased risk for culling [3].

Numerous studies have shown that dietary omega-3 (n-3) fatty acids have positive effects on reproductive and physiological properties in dairy cows [4–8]. In addition, changing omega-6 (n-6) to n-3 ratio in the diet is also a well-known strategy for affecting the endocannabinoid system (ECS), and the possible consequences of this change in ECS activity on peripartum dairy cows is yet to be explored [9, 10]. In dairy cows, the AT and liver have a major role in energy metabolism, and the ECS may play a crucial role in activation of lipogenesis and adipogenesis as well as inhibition of lipolytic activity [11]. Previously, the presence of key elements of the ECS in subcutaneous AT of dairy cows was established, and elevated levels of endocannabinoids (eCBs) were measured in postpartum (PP) AT [9]. The ECS may also be related to inflammation in AT of dairy cows, as the presence of many inflammatory mediators were found to be higher in AT of cows with high lipolysis PP, coupled with higher expression of the cannabinoid-2 (CB2) receptor, and the enzymes required for the synthesis and degradation of one of the main eCBs which is anandamide (AEA) [12].

As mentioned above, dietary supplementation of n-3 fatty acids is a strategy to decrease the activation of the ECS by lowering the availability of arachidonic acid (AA; C20:4n-6), a precursor of eCB synthesis and eCB levels in tissues [9, 10]. The eCBs AEA and 2-arachidonoylglycerol (2-AG) are synthesized from AA and are hydrolyzed to AA and ethanolamine and glycerol by the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL), respectively [13]. Flaxseed oil is one of the richest sources of the n-3 fatty acid alpha-linolenic acid (C18:3n-3) [14]. At this time, it is not known whether reducing the ECS activity by n-3 supplemental diet could be beneficial to peripartum dairy cows; on one hand, it might promote AT lipolysis and lower intake, but on the other hand it might decrease inflammation. We hypothesized that supplementation of n-3 fatty acids will modulate AEA and 2-AG levels [15], affecting ECS components in blood, AT and liver; possibly associated with the metabolic and inflammatory responses of PP dairy cows.

## Methods

### Animals and experimental procedures

The experimental protocol for the study was approved by the Volcani Center Animal Care Committee (approval number IL 797/18), and was performed in accordance with the relevant guidelines and regulations. The experiment was conducted at the Volcani Center experimental dairy farm in Rishon Lezion, Israel. The experimental design was previously reported in detail in [16]. Briefly, the experiment was conducted with twenty-eight multiparous (mean parity  $3.8 \pm 1.4$ ; mean  $\pm$  SD) high-yielding Israeli-Holstein dairy cows at 257 days of pregnancy, during the winter season. The cows were group-housed in a shaded loose pen that was equipped with a real-time electronic individual feeding system. The cows were stratified according to milk yields during the first 60 days of previous lactation, body weight (BW) at drying off and parity. The cows were examined by a veterinarian 5 to 10 days postpartum (PP), according to the routine management in Israel. The dietary treatments started at 257 days of pregnancy and continued until 60 days in lactation as follows: (i) CTL ( $n = 14$ ) – fed a basal diet, supplemented with encapsulated saturated fat at 240 and 560 g/day per cow prepartum and PP, respectively; (ii) FLX ( $n = 14$ ) – fed the same basal diet, supplemented prepartum at 300 g/day per cow with encapsulated fat providing  $\alpha$ -linolenic acid (ALA) at 56.1 g/day, and PP at 700 g/day per cow providing 131.0 g/day ALA from FLX. The fat content of the CTL supplement was 99% compared to 80% in the FLX; therefore, the supplemented amounts were different among groups to maintain similar contents of fat in all diets. The fat supplements were specially prepared and supplied by SILA (Venice, Italy). The ingredients and chemical composition of the rations PP, and the profile of the main fatty acids of the supplements are presented in [16]. The cows were milked thrice daily (at 05:00, 13:00, and 20:00 h), and milk production and BW were recorded automatically at the milking parlor (SAE, Kibbutz Afikim, Israel). Milk samples were collected every two weeks and analyzed for milk fat, protein, lactose and urea by infrared analysis (standard IDF 141C:2000) at the laboratories of the Israeli Cattle Breeders' Association (Caesarea, Israel). Energy balance was calculated according to NRC (2001)[17]. Blood samples were collected twice a week at 0700 h, and centrifugation was done at  $4000 \times g$  for 15 min for plasma followed by placing at  $-80^{\circ}\text{C}$  pending analysis. An additional blood sample was collected once a week in EDTA-tubes for RNA extraction.

### **Fatty acid composition in plasma**

Fatty acid (FA) composition in the plasma at week 1–2 PP was determined in 10 cows (5 cows from each group) as described in [18]. Briefly, the samples were saponified in a mixture of 60% KOH and ethanol, extracted with petroleum ether, and methylated with 5% (v/v) sulfuric acid in methanol. FA methyl esters were analyzed with a model 7890N gas chromatograph (Agilent Technologies, Santa Clara, CA, USA) equipped with a DB-23 capillary column (60 m  $\times$  0.25 mm  $\times$  0.25  $\mu\text{m}$ ; Agilent Technologies) and a flame ionization detector. The initial temperature of the column was set at  $130^{\circ}\text{C}$ , increased at  $6.5^{\circ}\text{C}/\text{min}$  to  $170^{\circ}\text{C}$ , and then at  $2.75^{\circ}\text{C}/\text{min}$  to  $215^{\circ}\text{C}$ , and held at  $215^{\circ}\text{C}$  for 18 min. Then, the temperature was increased to  $230^{\circ}\text{C}$  at a rate of  $40^{\circ}\text{C}/\text{min}$  for the remainder of the analysis. The carrier gas was hydrogen, flowing at a linear velocity of 1.6 mL/min; injection volume was 1  $\mu\text{L}$ .

### **Analysis of circulating metabolic parameters**

Plasma samples were analyzed for concentrations of non-esterified fatty acids [NEFAs; NEFA C Test Kit (Wako Chemicals GmbH, Neuss, Germany)],  $\beta$ -hydroxybutyric acid [BHBA; Ranbut D-3-Hydroxybutyrate kit (Randox, Crumlin, UK)], cortisol (EIA1887, DRG International, Inc., Springfield, NJ, USA), glucose, triglyceride (TG), and aspartate aminotransferase (AST; Cobas C111 Chemistry Analyzer, Roche Holding GmbH, Grenzach-Wyhlen, Germany).

### **Adrenocorticotrophic hormone administration (ACTH) in-vivo Challenge**

In order to examine the possible effect of n-3 supplementation on the acute stress response of postpartum cows, we performed an adrenocorticotrophic hormone (ACTH) challenge on d 21 PP according to [19]. Briefly, 5 cows from each treatment (n =10) were injected with 20 micrograms of Synacthen (analog for ACTH, Link Pharmaceuticals Ltd, Auckland, New Zealand). Blood samples were taken at six time points; at 5 minutes before the injection, at the time of the injection, followed by sampling at 15, 30, 45 and 60 minutes post injection. Cortisol concentrations were measured using an ELISA kit (DRG International Inc., Springfield, NJ, USA).

### **PBMC isolation**

Peripheral blood mononuclear cells (PBMC), collected during the 1<sup>st</sup> week PP, were used for proteomic analysis that was previously reported [16]; thus, for immunoblots in the present study we examined PBMC from the following sampling (on average  $17 \pm 3$  d PP; n = 5 from each treatment). PBMC were extracted from blood as previously described [16]. Briefly, fresh whole blood sample was diluted at 1:1 ratio using PBS along with phosphatase and protease inhibitors [(10mM sodium fluoride; 1mM sodium orthovanadate and 10mM sodium  $\beta$ -glycerophosphate (Sigma-Aldrich, St. Louis, MO, USA)]. The PBMC were isolated by centrifugation using a Ficoll layer (Histopaque 1077, Sigma-Aldrich). The buffy coat, containing the PBMC, was collected followed by a wash with cold PBS. The viable cells were counted using Trypan blue before bringing them to  $1 \times 10^7$  cells/mL concentration with PBS containing protease and phosphatase inhibitors (phosphatase inhibitor cocktail, protease inhibitor cocktail, 1% v/v each, Sigma-Aldrich). The cells were frozen at  $-80^\circ\text{C}$  for further protein extraction and immunoblotting.

### **Subcutaneous adipose tissue biopsy**

Subcutaneous AT biopsies from the fat pad around the pin bones were taken from a subset of 6 cows of each treatment at  $7.7 \pm 1.9$  d PP, as previously described [18]. In short, the biopsy site, a  $5 \times 5$  cm area of skin on one side of the pin bone, was prepared by clipping, washing and sterilizing. Cows were sedated with an intramuscular administration of 1 mL of 2% Sedaxylan (xylazine base, 20 mg/mL; Eurovet Animal Health, AE Bladel, the Netherlands). The biopsy site was anesthetized by an 8 mL subcutaneous injection of 2% lidocaine HCl (Esracain 2%, 200 mg per 10 mL; Rafa Laboratories Ltd, Israel). A 1.5 to 2.5 cm scalpel incision was made, under aseptic conditions, through the skin and subcutaneous tissues. In each cow, four samples of approximately 40 mg of fat tissue were captured using tweezers and scissors, tissue samples were then washed with saline followed by snap freeze in liquid nitrogen and then stored at

-80°C. Additional AT samples that were collected were fixed with 4% paraformaldehyde (Sigma-Aldrich) for histology (n = 4 from each treatment).

### **Liver biopsy**

Liver biopsies were conducted from 5 cows of each treatment at  $10.2 \pm 1.0$  d PP as previously described [20]. Briefly, the biopsy was taken from the right side of the animal through the intercostal space. An incision of approximately 1 cm was made through the skin and a few samples were collected under an ultrasound guidance using a 14 G  $\times$  20 cm needle (Aquila; Pie Medical Imaging BV, Maastricht, the Netherlands Bard Magnum; Bard Biopsy Systems, Tempe, AZ, USA). The liver samples (~25 mg each) were snap frozen in liquid nitrogen and stored at -80°C pending analysis. The incision site was stapled, treated topically with iodine spray and staples were removed after 7 to 10 d.

### **Endocannabinoid measurements**

The eCB levels were determined in plasma and liver at the day of the liver biopsy, and in AT samples. Levels of 2-AG, AEA, palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and AA were isolated, purified, and measured by the stable isotope dilution LC-MS/MS method [21].

### **Histology and adipocyte analysis**

AT samples (n = 4 from each treatment) were stained with H&E and imaged with an Olympus BX60 microscope at a magnification of X10 and the Olympus DP73 microscope's camera (Tokyo, Japan). Two replicates were obtained from each AT sample, and images were analyzed for adipocyte area at 10x magnification by the Adiposoft plugin (v. 1.15) for ImageJ Fiji (v 2.0.0) as described [22]. Images were spot checked for appropriate quantification. All image capture and analysis were carried out with random identifiers to blind the operator to the treatment of the cow.

### **Measurements of hepatic triglycerides and carbohydrates**

Tissue TG and carbohydrates (CH) were extracted as described in [23] and were quantified using Cobas C111 Chemistry Analyzers (Roche, Basel, Switzerland). Data were normalized according to tissue weight.

### **Quantitative real-time PCR**

RNA extraction of white blood cells (WBC) was performed by a leukocyte RNA purification kit (NORGEN BioTek Corp, Ontario, Canada) in blood samples collected at  $6 \pm 3$  d PP (n = 6 per treatment) using a 2 mL sample of fresh whole blood. Liver (25 mg) and AT (40 mg) samples were homogenized and RNA was extracted using a Tissue Purification Kit (NORGEN BioTek Corp, Ontario, Canada). The RNA purity was assessed using a Nanodrop with 260/280 ratio of above 1.85. First-strand cDNA was generated using a cDNA reverse transcription kit (K1622, RevertAid cDNA Synthesis Kit, Thermo Fisher Scientific, Vilnius, Lithuania). Quantitative real-time PCR was performed using a StepOnePlus instrument (QuantStudio 6 Flex Real-Time PCR System, Applied Biosystems, Foster City, CA, USA) using SYBR green PCR mix

(Invitrogen, Carlsbad, CA, USA). The examined genes and their primers are listed in Supplementary Table 1. In all tissues we examined the expression of ECS related genes and inflammatory related genes. In AT and liver samples we also examined gene expression of lipid metabolism and beta-oxidation related genes (Supplementary table 1), the primers of which were chosen according to [24]. All other primers were designed for bovine as described in [9]. Primers were validated before use and are detailed in Supplementary table 1. The WBC were normalized by using two reference genes; Glyceraldehyde-3-Phosphate Dehydrogenase (*GAPDH*) and Beta-Actin (*B-Actin*). The liver samples were normalized by using *GAPDH* and Tyrosine 3-Monooxygenase (*YWHAZ*) and the AT was normalized by *GAPDH* and Hypoxanthine Phosphoribosyltransferase 1 (*HPRT1*). The relative quantity of each gene was normalized to the average expression of the reference genes according to MIQE guidelines [25].

## Immunoblot analysis

Proteins from PBMC, AT and liver were extracted using 5 % SDS in 100mM Tris-HCL lysis buffer containing 1% PMSF, 1% phosphatase inhibitor cocktail and 1% protease inhibitor (Sigma-Aldrich). The samples protein concentrations were measured using the BCA Standard Kit (Cyanagen, Bologna, Italy). Samples were prepared in Laemmli loading buffer (Bio-Rad, Hercules, CA, USA) and resolved by SDS-PAGE under reducing conditions following a transfer to nitrocellulose membrane. The list of antibodies used, their dilutions and source are detailed in Supplementary Table 2. All samples were normalized by the protein abundance of beta-actin (1:1000, ab46805, Rabbit  $\alpha$  Bovine, Abcam Biotech, Cambridge, UK). Goat anti-rabbit HRP-conjugated secondary antibody (Jackson ImmunoResearch; 111-035-003, PA, USA) at a concentration of 1:10,000 was used for all proteins except DAGLA, in which the 2<sup>nd</sup> Ab was Donkey anti Goat HRP-conjugated (1:10,000, ab97110, Abcam biotech). The development was achieved by an ECL reaction for protein detection (Thermo Fisher Scientific, Waltham, MA, USA). Data was processed and analyzed by densitometry using ImageJ software (NIH, Bethesda, MD). To ensure that quantitative data were obtained, chemiluminescence signals were measured during at least five consecutive exposure times to determine each antibody's linear range of signal intensity. In liver samples, one CTL cow was excluded from analysis due to a technical problem with the protein lysate.

## Statistical analysis

Continues variables such as milk production, feed intake and energy balance, as well as plasma concentrations of metabolites and hormones were analyzed by repeated measurements PROC MIXED, using the following model:

$$Y_{ijkl} = \mu + T_i + C(T)_{ij} + DIM_{ijk} + E_{ijkl},$$

where  $\mu$  = overall mean;  $T_i$  = treatment effect ( $i$  = CTL or FLX);  $C(T)_{ij}$  = cow  $j$  nested in treatment  $i$ ;  $DIM_{ijk}$  = day in lactation as a continuous variable;  $E_{ijkl}$  = random residual.

Protein and gene abundances, plasma fatty acid profile, body weight loss, plasma cortisol in response to ACTH challenge, TG and CH in liver were analyzed by SAS GLM (version 9.2, 2002). The distribution of

adipocyte sizes and values of eCBs levels in plasma, liver and AT are shown as the mean  $\pm$  SEM, and were analyzed by unpaired two-tailed Student's t-test.

## Results

### Performance and the metabolic state of the cows

The FLX supplementation altered plasma FA composition; FLX increased the plasma percentage of alpha-linolenic acid (C18:3n-3) compared to control cows (3.9% and 1.8 in FLX and CTL, respectively, SEM = 0.15,  $P=0.001$ ), and the total n-3 FA percentage in plasma was higher in the FLX cows (5.0% vs. 2.6 in FLX and CTL, respectively, SEM = 0.17,  $P<0.0001$ ). The n-6/n-3 FA ratio in plasma tended to decrease in the FLX compared to CTL (24.2 and 9.8 in CTL and FLX respectively, SEM = 5.32,  $P=0.07$ ). Milk production, feed intake, energy balance and plasma indices of metabolic state during the first 14 d in lactation are presented in Table 1. Milk yields ( $P=0.20$ ) and fat corrected milk 4% ( $P=0.94$ ) were similar among groups, while the average dry matter intake was lower in the FLX than in the CTL ( $P=0.005$ ), and the average calculated energy balance was not different between groups ( $P=0.22$ ; Table 1). The BW loss between week 1 and week 3 PP was not different between groups (36.5 vs. 31.0 kg in CTL and FLX, respectively, SEM = 3.97,  $P=0.34$ ). During the first 14 d PP, average concentrations of NEFA, glucose, BHBA, AST, and TG did not differ between groups, while plasma cortisol was lower in FLX than in CTL ( $P=0.05$ ; Table 1). However, in response to an ACTH challenge at 21 d PP, average plasma cortisol concentrations were not different between CTL and FLX cows (39.4 and 40.3 ng/ml, in CTL and FLX, respectively, SEM = 5.24,  $P=0.90$ ; Supplementary Fig. 1).

Table 1

Milk production, feed intake, energy balance and plasma and liver indices of metabolic state during the first 14 d in lactation of dairy cows supplemented with n-3 fatty acids from flaxseed

	Treatment <sup>1</sup>			
	Control	FLX	SEM	P-value
Milk production, kg/d	36.1	33.5	1.35	0.20
Fat corrected milk 4%, kg/d	33.8	33.9	1.54	0.94
Dry matter intake, kg/d	22.2	20.4	0.42	<0.01
Energy balance, Mcal/d	-1.7	-3.5	1.01	0.22
NEFA <sup>2</sup> , $\mu$ Eq/L	584.4	509.7	69.19	0.46
Glucose, mg/dL	58.9	59.1	1.21	0.88
BHBA <sup>3</sup> , mg/dL	0.6	0.7	0.06	0.18
AST <sup>4</sup> , u/L	959.4	979.2	24.60	0.58
TG <sup>5</sup> , mg/dL	10.8	11.8	0.57	0.24
Cortisol, ng/ml	9.6	5.9	1.17	0.05
Liver Tg <sup>5</sup> , mg/gr	111.5	100.5	5.60	0.24
Liver CH <sup>6</sup> , mg/gr	7.7	5.2	1.37	0.23

<sup>1</sup>Dairy cows were divided into two nutritional regiment groups from -21–60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup>Non-esterified fatty acids; <sup>3</sup>Beta-hydroxybutyrate; <sup>4</sup>Aspartate aminotransferase; <sup>5</sup>Triglycerides; <sup>6</sup>Carbohydrates.

## Effects Of Dietary N-3 On Ecs Components In Blood

As shown in Table 2, at 10 d PP the average plasma levels of AEA ( $P=0.03$ ) and AA ( $P=0.02$ ) were nearly 2 fold lower in FLX compared to CTL, while levels of 2-AG, PEA and OEA were not different between

groups. In WBCs during the 1st week PP, the relative gene expression of *CNR1*, but not *CNR2* or *MGLL*, tended to be lower in the FLX compared to CTL (0.005 vs. 0.002 RQ in the CTL and FLX, respectively, SEM = 0.001,  $P=0.10$ ). In PBMCs, the average protein abundance of CB1 (0.381 vs. 0.600 AU in CTL and FLX, respectively, SEM = 0.22,  $P=0.50$ ) and CB2 (0.439 vs. 0.534 AU in CTL and FLX, respectively, SEM = 0.13,  $P=0.62$ ) were not different between treatments, but the abundance of MGLL was higher in FLX than in CTL (0.835 vs. 1.394 AU in CTL and FLX, respectively, SEM = 0.16,  $P=0.04$ ).

Table 2  
eCB concentrations in plasma, liver and AT samples of PP dairy cows supplemented with n-3 fatty acids from flaxseed.

	Treatment <sup>1</sup>			
	CTL	FLX	SEM	P -value
<b>Plasma</b>				
2-AG <sup>2</sup> ,(fmol/mL)	10.5	9.1	2.13	0.65
AA <sup>3</sup> , (pmol/mL)	581.2	324.3	61.18	0.02
AEA <sup>4</sup> , (fmol/mL)	232.2	116.8	31.82	0.03
PEA <sup>5</sup> , (fmol/mL)	0.4	0.0	0.31	0.33
OEA <sup>6</sup> , (fmol/mL)	34.1	34.3	9.66	0.99
<b>Adipose</b>				
2-AG <sup>2</sup> ,(fmol/mg)	97.0	69.6	25.90	0.48
AA <sup>3</sup> , (pmol/mg)	1.3	1.0	0.16	0.24
AEA <sup>4</sup> , (fmol/mg)	0.7	0.7	0.17	0.97
PEA <sup>5</sup> , (fmol/mg)	16.1	6.2	2.53	0.02
OEA <sup>6</sup> , (fmol/mg)	125.2	100.2	15.90	0.30
<b>Liver</b>				
2-AG <sup>2</sup> ,(fmol/mg)	287.6	497.8	72.03	0.07
AA <sup>3</sup> , (pmol/mg)	6.9	8.2	1.65	0.59
AEA <sup>4</sup> , (fmol/mg)	0.7	0.9	0.40	0.73
PEA <sup>5</sup> , (fmol/mg)	13.9	10.6	8.17	0.78
OEA <sup>6</sup> , (fmol/mg)	44.2	15.9	15.16	0.22

<sup>1</sup>Dairy cows were divided into two nutritional regiment groups from - 21–60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup>2-Arachidonoylglycerol; <sup>3</sup>Arachidonic acid; <sup>4</sup>Anandamide; <sup>5</sup>N-palmitoylethanolamine; <sup>6</sup> N-Oleoylethanolamine. Liver samples were taken from 5 cows per treatment at 10.2 ± 1.0 DIM while AT samples were obtained from 6 cows from each treatment at 7.7 ± 1.9 DIM.

# Effects Of Dietary N-3 On Ecs Components In Adipose Tissue

In the AT collected at 7 d PP, the PEA levels decreased by 2.6 fold in the FLX compared to the CTL ( $P=0.02$ ), while no differences were observed in the levels of 2-AG, AA, AEA, and OEA between groups (Table 2). The expression of genes related to lipid metabolism and FA  $\beta$ -oxidation were higher in FLX vs. CTL: the average relative expressions of *HSL* ( $P=0.02$ ), *ChREBP* ( $P=0.01$ ), *ACO* ( $P=0.0009$ ), *SREBP-1* ( $P=0.01$ ) and *PPARG* ( $P=0.04$ ) were higher in FLX than in CTL, and *ACSL1* tended to be higher in FLX than in CTL ( $P=0.07$ ; Table 3). No differences were found between groups in the gene expression of *PPARA*, *FABP4*, *CPT1* or *CPT2*, *CNR1*, *CNR2*, *MGLL*, *NAPEPLD*, *PPARA*, *FAAH*, *TNFA*, *IL-1B*, *IL-6*, *NFkB*, *TLR4*, *CD14*, *IL-10*, *PTGS2*, *FASN* and *PLA2* (Table 3). As shown in Fig. 1, the protein abundance of CB2 in AT tended to be higher in FLX compared to CTL ( $P=0.08$ ), and MGLL tended to be higher in FLX compared to CTL ( $P=0.10$ ). The protein abundances of CB1, DAGLA and FAAH in AT did not differ among groups (Supplementary Table 3). In addition, the average protein abundance of NFkB, TNF- $\alpha$ , IL-10, HSL, and FASN were not different between groups (Supplementary Table 3). Analyzing the distribution of adipocytes from different sizes demonstrated a tendency for a higher percentage of relatively large ( $4001-6000 \mu\text{M}^2$ ) adipocytes in FLX compared to CTL ( $P=0.07$ ), while other cell sizes were similarly distributed among groups (Supplementary Fig. 2).

Table 3

Adipose tissue average gene expression (relative quantities; RQ) of ECS-related, lipid metabolism and inflammatory genes of PP dairy cows supplemented with n-3 fatty acids.

Treatment <sup>1</sup>				
	Control	FLX	SEM	P-value
<b>RQ</b>				
<b>Endocannabinoid-related</b>				
<i>CNR1</i> <sup>2</sup>	1.65	1.71	0.090	0.672
<i>CNR2</i> <sup>3</sup>	0.34	0.30	0.023	0.249
<i>MGLL</i> <sup>4</sup>	0.68	0.76	0.082	0.547
<i>NAPEPLD</i> <sup>5</sup>	0.02	0.03	0.004	0.120
<i>FAAH</i> <sup>6</sup>	0.07	0.08	0.033	0.897
<b>Lipid metabolism and beta oxidation</b>				
<i>PPARA</i> <sup>7</sup>	0.08	0.13	0.022	0.217
<i>PPARG</i> <sup>8</sup>	0.52	1.35	0.246	0.039
<i>HSL</i> <sup>9</sup>	1.67	12.46	2.894	0.025
<i>FASN</i> <sup>10</sup>	0.80	1.97	0.577	0.185
<i>FABP4</i> <sup>11</sup>	61.18	147.02	42.787	0.186
<i>SREBP-1</i> <sup>12</sup>	0.35	0.73	0.093	0.015
<i>ChREBP</i> <sup>13</sup>	0.04	0.15	0.027	0.015
<i>ACO</i> <sup>14</sup>	0.13	0.53	0.060	< 0.001

<sup>1</sup>Dairy cows were divided into two nutritional regiment groups from - 21 – 60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup>Cannabinoid-1 Receptor; <sup>3</sup>Cannabinoid-2 Receptor; <sup>4</sup>Monoglyceride Lipase; <sup>5</sup>N-Acyl Phosphatidylethanolamine Phospholipase D; <sup>6</sup>Fatty Acid Amide Hydrolase; <sup>7</sup>Peroxisome Proliferator Activated Receptor Alpha; <sup>8</sup>Peroxisome Proliferator Activated Receptor Gamma; <sup>9</sup>Hormone Sensitive Lipase; <sup>10</sup>Fatty Acid Synthase; <sup>11</sup>Fatty Acid Binding Protein 4; <sup>12</sup>Sterol Regulatory Element Binding Transcription Factor 1; <sup>13</sup>Carbohydrate response element binding protein; <sup>14</sup>Acyl-CoA oxidase; <sup>15</sup>Acyl-CoA Synthetase Long Chain Family Member 1; <sup>16</sup>carnitine palmitoyltransferase 1; <sup>17</sup>carnitine palmitoyltransferase 2; <sup>18</sup>Tumor necrosis factor  $\alpha$ ; <sup>19</sup>Interleukin 1 beta; <sup>20</sup>Interleukin 6; <sup>21</sup>Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells; <sup>22</sup>Toll Like Receptor 1; <sup>23</sup>CD14 Molecule 10; <sup>24</sup>Prostaglandin Endoperoxide Synthase 2; <sup>25</sup>Phospholipase A2 Group IIA; <sup>26</sup>Interleukin 10.

	Treatment <sup>1</sup>			
<i>ACSL1</i> <sup>15</sup>	0.26	0.62	0.128	0.077
<i>CPT1</i> <sup>16</sup>	0.02	0.09	0.034	0.144
<i>CPT2</i> <sup>17</sup>	0.76	1.00	0.122	0.205
<b>Inflammation</b>				
<i>TNF-A</i> <sup>18</sup>	0.005	0.003	0.001	0.227
<i>IL-1B</i> <sup>19</sup>	0.02	0.01	0.010	0.296
<i>IL-6</i> <sup>20</sup>	0.60	0.57	0.077	0.835
<i>NFKB</i> <sup>21</sup>	0.06	0.11	0.034	0.327
<i>TLR4</i> <sup>22</sup>	0.15	0.12	0.03	0.496
<i>CD14</i> <sup>23</sup>	0.55	0.52	0.05	0.706
<i>PTGS2</i> <sup>24</sup>	0.68	0.76	0.082	0.547
<i>PLA2</i> <sup>25</sup>	0.36	0.29	0.067	0.489
<i>IL-10</i> <sup>26</sup>	0.007	0.009	0.002	0.480
<p><sup>1</sup>Dairy cows were divided into two nutritional regiment groups from - 21 – 60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup>Cannabinoid-1 Receptor; <sup>3</sup>Cannabinoid-2 Receptor; <sup>4</sup>Monoglyceride Lipase; <sup>5</sup>N-Acyl Phosphatidylethanolamine Phospholipase D; <sup>6</sup>Fatty Acid Amide Hydrolase; <sup>7</sup>Peroxisome Proliferator Activated Receptor Alpha; <sup>8</sup>Peroxisome Proliferator Activated Receptor Gamma; <sup>9</sup>Hormone Sensitive Lipase; <sup>10</sup>Fatty Acid Synthase; <sup>11</sup>Fatty Acid Binding Protein 4; <sup>12</sup>Sterol Regulatory Element Binding Transcription Factor 1; <sup>13</sup>Carbohydrate response element binding protein; <sup>14</sup>Acyl-CoA oxidase; <sup>15</sup>Acyl-CoA Synthetase Long Chain Family Member 1; <sup>16</sup>carnitine palmitoyltransferase 1; <sup>17</sup>carnitine palmitoyltransferase 2; <sup>18</sup>Tumor necrosis factor <math>\alpha</math>; <sup>19</sup>Interleukin 1 beta; <sup>20</sup>Interleukin 6; <sup>21</sup>Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells; <sup>22</sup>Toll Like Receptor 1; <sup>23</sup>CD14 Molecule 10; <sup>24</sup>Prostaglandin Endoperoxide Synthase 2; <sup>25</sup>Phospholipase A2 Group IIA; <sup>26</sup>Interleukin 10.</p>				

## Effects Of Dietary N-3 On Ecs Components In Liver

In the liver, the average levels of 2-AG tended to increase in FLX compared to the control ( $P= 0.07$ ), but the levels of AA, AEA, PEA and OEA did not differ among groups (Table 2). No differences were found in the levels of triglycerides or carbohydrate in the liver (Table 1). As shown in Table 4, the relative gene

expression of *CNR1* ( $P=0.11$ ) and *CNR2* ( $P=0.07$ ) in liver tended to be lower in the FLX compared to the CTL, whereas no changes were observed in the gene expression of *MGLL*, *NAPEPLD* and *FAAH*. A 1.4-fold decrease in pro-inflammatory *IL6* was found in the FLX compared to the control ( $P=0.03$ ), while no significant changes were neither documented in the inflammatory genes *TNFA*, *IL1B*, *NFkB*, *SAA2*, *Hp* and *IL10* nor in the lipid metabolism genes *PPARA*, *SREBP1*, *ChREBP*, *ACO*, *ACSL1*, *LFABP*, *CPT1*, and *CPT2* among treatments (Table 4). As shown in Fig. 2, the average protein abundance of NFkB in the liver tended to increase in the FLX compared to CTL ( $P=0.06$ ), while the abundances of CB1, DAGLA and MGLL were not different between groups. Average liver protein abundances of FAAH, IL-10 and TNF- $\alpha$  were also not different between treatments (Supplementary table 4).

Table 4

Liver average gene expression (relative quantities; RQ) of ECS-related, lipid metabolism and inflammatory genes of PP dairy cows supplemented with n-3 fatty acids.

RQ	Treatment <sup>1</sup>			P-value
	Control	FLX	SEM	
<b>Endocannabinoid-related</b>				
<i>CNR1</i> <sup>2</sup>	0.05	0.03	0.007	0.11
<i>CNR2</i> <sup>3</sup>	0.71	0.46	0.083	0.07
<i>MGLL</i> <sup>4</sup>	2.65	2.24	0.528	0.60
<i>NAPEPLD</i> <sup>5</sup>	0.06	0.07	0.006	0.49
<i>FAAH</i> <sup>6</sup>	1.71	1.78	0.240	0.85
<b>Lipid metabolism and beta oxidation</b>				
<i>PPARA</i> <sup>7</sup>	6.76	9.17	1.620	0.32
<i>SREBP-1</i> <sup>8</sup>	1.22	1.26	0.135	0.87
<i>ChREBP</i> <sup>9</sup>	1.45	1.64	0.310	0.67
<i>ACO</i> <sup>10</sup>	29.39	35.70	5.074	0.41
<i>ACSL 1</i> <sup>11</sup>	18.28	13.74	3.413	0.37
<i>LFABP</i> <sup>12</sup>	83.21	116.75	16.969	0.20
<i>CPT1</i> <sup>13</sup>	1.12	0.42	0.371	0.22
<i>CPT2</i> <sup>14</sup>	8.89	7.87	1.432	0.63
<b>Inflammation</b>				

<sup>1</sup>Dairy cows were divided into two nutritional regiment groups from - 21 – 60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup>Cannabinoid-1 Receptor; <sup>3</sup>Cannabinoid-2 Receptor; <sup>4</sup>Monoglyceride Lipase; <sup>5</sup>N-Acyl Phosphatidylethanolamine Phospholipase D; <sup>6</sup>Fatty Acid Amide Hydrolase; <sup>7</sup>Peroxisome Proliferator Activated Receptor Alpha; <sup>8</sup>Sterol Regulatory Element Binding Transcription Factor 1; <sup>9</sup>Carbohydrate response element binding protein; <sup>10</sup>Acyl-CoA oxidase; <sup>11</sup> Acyl-CoA Synthetase Long Chain Family Member 1; <sup>12</sup>Liver Fatty Acid-Binding Protein; <sup>13</sup>carnitine palmitoyltransferase 1; <sup>14</sup>carnitine palmitoyltransferase 2; <sup>15</sup>Tumor necrosis factor  $\alpha$ ; <sup>16</sup>Interleukin 1 beta; <sup>17</sup>Interleukin 6; <sup>18</sup>Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells; <sup>19</sup>Serum Amyloid A2; <sup>20</sup>Haptoglobin; <sup>21</sup>Interleukin 10.

	Treatment <sup>1</sup>			
<i>TNF-A</i> <sup>15</sup>	0.02	0.03	0.005	0.24
<i>IL-1B</i> <sup>16</sup>	0.06	0.07	0.014	0.81
<i>IL-6</i> <sup>17</sup>	0.27	0.18	0.024	0.03
<i>NFkB</i> <sup>18</sup>	0.18	0.22	0.031	0.46
<i>SAA2</i> <sup>19</sup>	65.99	28.32	26.738	0.35
<i>HP</i> <sup>20</sup>	38.42	10.17	12.899	0.16
<i>IL-10</i> <sup>21</sup>	0.01	0.01	0.003	0.53
<sup>1</sup> Dairy cows were divided into two nutritional regiment groups from - 21 – 60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup> Cannabinoid-1 Receptor; <sup>3</sup> Cannabinoid-2 Receptor; <sup>4</sup> Monoglyceride Lipase; <sup>5</sup> N-Acyl Phosphatidylethanolamine Phospholipase D; <sup>6</sup> Fatty Acid Amide Hydrolase; <sup>7</sup> Peroxisome Proliferator Activated Receptor Alpha; <sup>8</sup> Sterol Regulatory Element Binding Transcription Factor 1; <sup>9</sup> Carbohydrate response element binding protein; <sup>10</sup> Acyl-CoA oxidase; <sup>11</sup> Acyl-CoA Synthetase Long Chain Family Member 1; <sup>12</sup> Liver Fatty Acid-Binding Protein; <sup>13</sup> carnitine palmitoyltransferase 1; <sup>14</sup> carnitine palmitoyltransferase 2; <sup>15</sup> Tumor necrosis factor $\alpha$ ; <sup>16</sup> Interleukin 1 beta; <sup>17</sup> Interleukin 6; <sup>18</sup> Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells; <sup>19</sup> Serum Amyloid A2; <sup>20</sup> Haptoglobin; <sup>21</sup> Interleukin 10.				

## Discussion

In the present study, we hypothesized that supplementing peripartum cows with n-3 fatty acids will lower the systemic availability of AA and reduce ECS activation in blood, liver and AT. Indeed, we found lower AA and AEA levels in plasma of FLX cows, along with lower PEA in AT and a tendency for higher 2-AG levels in the liver of FLX compared to CTL. This was accompanied by moderate changes in gene and protein abundances of ECS components in FLX tissues, such as a tendency for decreased *CNR1* and *CNR2* gene expression in the liver, and a tendency for increase in CB2 protein expression in the AT. Supplementation of n-3 was hypothesized to lower ECS activation, thus reduce feed intake, as in mammals CB1 activation in the brain increases feed intake [26]. Although we did not examine ECS components in the brain in this study, we have found a reduction in feed intake, which could be related to a certain alteration in the activation of the ECS in the FLX cows during the early PP period. This could be supported by the tendency for decreased gene expression of the CB1 receptor in both WBC and liver samples, which could possibly suggest a systemic reduction in ECS activity that was related to the lower intake. However, other studies in which n-3 from flaxseed was supplemented to peripartum cows showed increased intake compared with control cows [27], while others observed no effect of flaxseed supplementation on intake [28–30], or reduced intake [31]; possible causes for these inconsistencies were

described [32]. Nevertheless, our findings support the hypothesis that lower ECS activation may be related to lower feed intake in PP dairy cows.

We found a tendency toward lower gene expression of CB1 in WBC along with a higher protein abundance of MGLL in PBMC of FLX compared to CTL blood, although it was not translated into lower plasma 2-AG levels. In addition to the main role of the ECS as a regulator of energy metabolism, it is also involved in maintaining a balanced inflammatory and redox state [33]. The effects of ECS activation on inflammatory responses are complex and vary depending on the tissue, eCBs, and the type of receptor. For example, AEA has anti-inflammatory effects, including the inhibition of chemoattractant cytokines secretion, especially those released at the early stages of the inflammatory process such as IL-6, IL-8, and MCP-1, along with completely blocking lipopolysaccharide (LPS)-triggered activation of NF $\kappa$ B pathway in periodontal tissues [34]. As for the receptors, activation of the CB1 suppresses the proliferation of cells of the adaptive immune system, especially T-cells [35]. There are reports indicating that inhibition of ECS receptor activity causes inflammatory responses [36]. We have previously reported an enrichment of the acute-phase-signaling and complement pathways in PBMCs from FLX compared to CTL [16], and based on the moderate changes in CB1 and MGLL in WBC, we suggest that nutritional supplementation of n-3 might affect the inflammatory response of these cells via the ECS, however this premise requires further examination.

A reduction in ECS activation should coincide with increased lipolysis; however, we did not observe differences in body weight loss, plasma NEFAs and EB, and we found a tendency for a higher proportion of large adipocytes in AT of FLX compared to CTL, which does not support the hypothesis of increased lipolysis in these cows. We observed increased expression of several lipid metabolism genes (*HSL*, *FABP4*, *ChREBP*, *ACO*) in FLX AT, possibly suggesting increased lipogenesis in AT of cows supplemented with n-3. In adipocytes, CB1 receptor stimulation increases the uptake of glucose and lipogenesis while inhibiting lipolysis [37]. CB1 conducts its response via G protein Gi/o-mediated reduction in adenylate cyclase action, suppressing the activation of HSL through the halt in cyclic adenosine monophosphate (cAMP) production [38]. Higher gene expression of *CNR2*, *NAPEPLD*, and *FAAH* in AT coincides with enhanced expression of pro-inflammatory genes (*TNFA*, *IL6*, *IL1B*) at 21 and 42 days PP in cows exhibiting intense AT lipolysis [12]. The anti-lipolytic effect of CB1 stimulation in adipocytes occurs through Gi/o inhibition of cAMP production, which limits the downstream phosphorylation of HSL and perilipin [39]. Transcriptional effects downstream of CB1 activation in AT include the suppression of lipolysis-associated enzymes (carnitine-acyl-CoA transferase, carnitine palmitoyltransferase 2, and crotonase), along with downregulation of  $\beta$ -adrenergic and growth hormone receptor expression [40]. CB1 stimulation in AT sympathetic nerves suppresses catecholamine release, subsequently downregulating HSL activity through the decrease in cAMP produced by the AT [41]. Our findings may indicate of increased lipid metabolism, possibly promoting lipogenesis and thus limiting lipolysis in AT of FLX cows despite lower feed intake.

We found a tendency towards increased abundance of CB2 in FLX nutritional based AT. CB2 is found primarily in microvascular endothelial cells and on the surface of immune cells, most commonly those

derived from the hematopoietic lineage [42]. CB2 is known to exert anti-inflammatory effects in peripheral tissues [42], and only low levels of CB2 expression are detected in monogastric AT [43]. In humans, CB2 expression has been shown to decrease as pre-adipocytes mature into adipocytes in vitro [44]. This gene expression pattern suggests that within AT, CB2 content is higher in preadipocytes, macrophages, and vascular cells rather than in mature adipocytes [44]. Therefore, we assume that the increased CB2 in AT could suggest of a higher presence of immune cells in the AT of the FLX cows. The liver content of TG and CH was not different between groups, although plasma TG showed no difference between treatment groups. We found that the mRNA abundance of CB1 and CB2 tended to be lower in the liver of FLX cows, while 2-AG was higher and the expression of *IL6* was reduced in liver of FLX nutritional based cows, which could indicate of reduced inflammation in liver of FLX cows; although the abundance of NFKB tended to be higher in liver of FLX compared to CTL. Together, dietary n-3 had a moderate effect on some ECS components in the liver of PP cows; it is suggested that the higher 2-AG could be a local response to the systemic reduction in ECS tone and may be related to a possible lower inflammatory tone in the liver, however this requires further investigation.

## Conclusions

Dietary supplementation of n-3 fatty acids reduced plasma levels of AA and AEA, and tended to reduce gene expression of *CNR1* in WBC and liver during the early PP period compared to controls, indicating a possible reduction in ECS activation that could be related to the decreased feed intake. However, similar body weight loss, plasma NEFAs, energy balance, and increased cell size in AT of FLX do not support increased lipolysis in these cows. Nonetheless, some moderate alterations in ECS components were evident in blood, liver and AT, possibly indicating of increased lipid metabolism in AT and lower inflammation in liver, as shown in our proposed model in Fig. 3. Together, our findings demonstrate that nutritional supplementation of n-3 FA has a moderate effect on ECS components and may be related to the metabolic and inflammatory responses in AT and liver of peripartum dairy cows.

## Abbreviations

2-AG  
2-arachidonoylglycerol  
AA  
arachidonic acid  
ACTH  
adrenocorticotrophic hormone  
AEA  
anandamide  
ALA  
 $\alpha$ -linolenic acid  
AST  
aspartate aminotransferase

AT  
adipose tissue  
BHBA  
 $\beta$ -hydroxybutyric acid  
BW  
body weight  
CB1  
cannabinoid receptor 1  
CB2  
cannabinoid receptor 2  
CH  
carbohydrates  
eCBs  
endocannabinoids  
ECS  
endocannabinoid system  
FA  
Fatty acid  
FAAH  
fatty acid amide hydrolase  
MGLL  
monoacylglycerol lipase  
n-3  
omega-3  
n-6  
omega-6  
NEFAs  
non-esterified fatty acids  
OEA  
oleoylethanolamide  
PBMC  
Peripheral blood mononuclear cells  
PEA  
palmitoylethanolamide  
PP  
postpartum  
TG  
triglycerides  
WBC  
white blood cells

## Declarations

**Ethics approval and consent to participate:** The experimental protocol for the study was approved by the Volcani Center Animal Care Committee (approval number IL 797/18), and was performed in accordance with the relevant guidelines and regulations.

**Consent for publication:** Not applicable

**Availability of data and material:** All data generated or analysed during this study are included in this published article and its supplementary information files.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** This research was supported by Research Grant No. IS-5167-19 from BARD, The United States–Israel Binational Agricultural Research and Development Fund (Rishon LeZion, Israel) to J.T., G.A.C. and M.Z.; J.R.D. received a postdoc scholarship from the Israeli Ministry of Foreign Affairs.

**Authors' contributions:** Conceptualization, M.Z., J.T., G.A.C.; methodology, G.K., H.K., U.M., A.N.; validation, G.K., M.Z.; formal analysis, G.K., M.Z., J.T., R.K., A.N.; data curation, G.K., J.R.D.; writing—original draft preparation, G.K., M.Z.; writing—review and editing, J.T., G.A.C., U.M. and M.Z.; visualization, G.K., J.R.D.; supervision, J.T. and M.Z. Funding acquisition M.Z., J.T., G.A.C. All authors read and approved the final manuscript.

**Acknowledgements:** The authors thank the staff of the Dairy Cattle Experimental Farm of the Volcani Center (Rishon LeZion, Israel) for their assistance with animal care during conduct of this experiment. The authors also wish to thank Mr. Maurizio Lorenzon and the SILA Company (Venice, Italy) for partly donating the fat supplements.

## References

1. Mann S, Sipka A, Leal Yepes FA, Nydam DV, Overton TR, Wakshlag JJ. Nutrient-sensing kinase signaling in bovine immune cells is altered during the postpartum nutrient deficit: A possible role in transition cow inflammatory response. *J Dairy Sci* [Internet]. American Dairy Science Association; 2018;101:9360–70. Available from: <http://dx.doi.org/10.3168/jds.2018-14549>.
2. Contreras GA, Sordillo LM. Lipid mobilization and inflammatory responses during the transition period of dairy cows. *Comp Immunol Microbiol Infect Dis* [Internet]. Elsevier Ltd; 2011;34:281–9. Available from: <http://dx.doi.org/10.1016/j.cimid.2011.01.004>.
3. Ospina PA, McArt JA, Overton TR, Stokol T, Nydam DV. Using nonesterified fatty acids and  $\beta$ -hydroxybutyrate concentrations during the transition period for herd-level monitoring of increased risk of disease and decreased reproductive and milking performance. *Vet Clin Food Anim Pract Elsevier*. 2013;29:387–412.

4. Moallem U, Shafran A, Zachut M, Dekel I, Portnick Y, Arieli A. Dietary  $\alpha$ -linolenic acid from flaxseed oil improved folliculogenesis and IVF performance in dairy cows, similar to eicosapentaenoic and docosahexaenoic acids from fish oil. 2010.
5. Moallem U, Kamer H, Hod A, Lifshitz L, Kra G, Jacoby S, et al. Reducing milking frequency from thrice to twice daily in early lactation improves the metabolic status of high-yielding dairy cows with only minor effects on yields. *J Dairy Sci.* 2019;102.
6. Zachut M, Arieli A, Moallem U. Incorporation of dietary n-3 fatty acids into ovarian compartments in dairy cows and the effects on hormonal and behavioral patterns around estrus. *Reproduction.* 2011;141:833–40.
7. Raphael W, Sordillo L. Dietary Polyunsaturated Fatty Acids and Inflammation: The Role of Phospholipid Biosynthesis. *Int J Mol Sci.* 2013;14:21167–88.
8. Sordillo LM. Nutritional strategies to optimize dairy cattle immunity<sup>1</sup>. *J Dairy Sci* [Internet]. 2016;99:4967–82. Available from: <https://www.sciencedirect.com/science/article/pii/S0022030216001004>.
9. Zachut M, Kra G, Moallem U, Livshitz L, Levin Y, Udi S, et al. Characterization of the endocannabinoid system in subcutaneous adipose tissue in periparturient dairy cows and its association to metabolic profiles. *PLoS ONE.* 2018;13:e0205996.
10. Zachut M. Letter to the editor: Are the physiological effects of dietary n-3 fatty acids partly mediated by changes in activity of the endocannabinoid system in dairy cows? *J. Dairy Sci. United States;* 2020. p. 1049.
11. Myers MN, Zachut M, Tam J, Contreras GA. A proposed modulatory role of the endocannabinoid system on adipose tissue metabolism and appetite in periparturient dairy cows. *J Anim Sci Biotechnol* [Internet]. *BioMed Central;* 2021;12:21. Available from: <https://pubmed.ncbi.nlm.nih.gov/33663611>.
12. Dirandeh E, Ghorbanalinia M, Rezaei-Roodbari A, Colazo MG. Relationship between body condition score loss and mRNA of genes related to fatty acid metabolism and the endocannabinoid system in adipose tissue of periparturient cows. *Animal.* 2020;14:1724–32.
13. Watson JE, Kim JS, Das A. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. *Prostaglandins Other Lipid Mediat.* 2019;143:106337.
14. Moallem U. Invited review: Roles of dietary n-3 fatty acids in performance, milk fat composition, and reproductive and immune systems in dairy cattle. *J Dairy Sci* [Internet]. *American Dairy Science Association;* 2018;101:8641–61. Available from: <http://dx.doi.org/10.3168/jds.2018-14772>.
15. Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Fatty Acid Modulation of the Endocannabinoid System and the Effect on Food Intake and Metabolism. Vinolo MAR, editor. *Int J Endocrinol* [Internet]. *Hindawi Publishing Corporation;* 2013;2013:361895. Available from: <https://doi.org/10.1155/2013/361895>.
16. Kra G, Nemes-Navon N, Daddam JR, Livshits L, Jacoby S, Levin Y, et al. Proteomic analysis of peripheral blood mononuclear cells and inflammatory status in postpartum dairy cows

- supplemented with different sources of omega-3 fatty acids. *J Proteomics* [Internet]. 2021;246:104313. Available from: <https://www.sciencedirect.com/science/article/pii/S1874391921002128>.
17. Council NR. *Nutrient Requirements of Dairy Cattle: Seventh Revised Edition, 2001* [Internet]. Washington, DC: The National Academies Press; 2001. Available from: <https://www.nap.edu/catalog/9825/nutrient-requirements-of-dairy-cattle-seventh-revised-edition-2001>.
  18. Zachut M, Honig H, Striem S, Zick Y, Boura-Halfon S, Moallem U. Periparturient dairy cows do not exhibit hepatic insulin resistance, yet adipose-specific insulin resistance occurs in cows prone to high weight loss. *J Dairy Sci United States*. 2013;96:5656–69.
  19. Trevisi E, Lombardelli R, Minuti A, Bertoni G. Adrenal responsiveness to a low-dose ACTH challenge in early and late lactating dairy cows. *Ital J Anim Sci*. 2009;8:661–3.
  20. Swartz TH, Moallem U, Kamer H, Kra G, Levin Y, Mamedova LK, et al. Characterization of the liver proteome in dairy cows experiencing negative energy balance at early lactation. *J Proteomics* [Internet]. Elsevier B.V.; 2021;246:104308. Available from: <https://doi.org/10.1016/j.jprot.2021.104308>.
  21. Montgomery SR, Mamedova LK, Zachut M, Kra G, Häussler S, Vaughn M, et al. Effects of sodium salicylate on glucose kinetics and insulin signaling in postpartum dairy cows. *J Dairy Sci* [Internet]. American Dairy Science Association; 2019;102:1617–29. Available from: <http://dx.doi.org/10.3168/jds.2018-15312>.
  22. Ferland DJ, Garver H, Contreras GA, Fink GD, Watts SW. Chemerin contributes to in vivo adipogenesis in a location-specific manner. *PLoS One* [Internet]. 2020;15:1–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0229251>.
  23. FOLCH J, LEES M, SLOANE, STANLEY GH. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem*. 1957;226:497–509.
  24. Chen H, Zhang L, Li X, Li X, Sun G, Yuan X, et al. Adiponectin activates the AMPK signaling pathway to regulate lipid metabolism in bovine hepatocytes. *J. Steroid Biochem. Mol. Biol*. 2013. p. 445–54.
  25. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. *Clin Chem* [Internet]. 2009;55:611–22. Available from: <https://doi.org/10.1373/clinchem.2008.112797>.
  26. Miller CC, Murray TF, Freeman KG, Edwards GL. Cannabinoid agonist. CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. *Physiol Behav United States*. 2004;80:611–6.
  27. Zachut M, Arieli A, Lehrer H, Livshitz L, Yakoby S, Moallem U. Effects of increased supplementation of n-3 fatty acids to transition dairy cows on performance and fatty acid profile in plasma, adipose tissue, and milk fat. *J Dairy Sci United States*. 2010;93:5877–89.
  28. Gonthier C, Mustafa AF, Ouellet DR, Chouinard PY, Berthiaume R, Petit HV. Feeding micronized and extruded flaxseed to dairy cows: Effects on blood parameters and milk fatty acid composition. *J Dairy Sci Elsevier*. 2005;88:748–56.

29. Ferlay A, Doreau M, Martin C, Chilliard Y. Effects of incremental amounts of extruded linseed on the milk fatty acid composition of dairy cows receiving hay or corn silage. *J Dairy Sci Elsevier*. 2013;96:6577–95.
30. Neveu C, Baurhoo B, Mustafa A. Effect of feeding extruded flaxseed with different grains on the performance of dairy cows and milk fatty acid profile. *J Dairy Sci Elsevier*. 2014;97:1543–51.
31. Martin C, Rouel J, Jouany JP, Doreau M, Chilliard Y. Methane output and diet digestibility in response to feeding dairy cows crude linseed, extruded linseed, or linseed oil. *J Anim Sci Oxford University Press*. 2008;86:2642–50.
32. Moallem U. Invited review: Roles of dietary n-3 fatty acids in performance, milk fat composition, and reproductive and immune systems in dairy cattle. *J Dairy Sci [Internet]*. American Dairy Science Association; 2018;101:8641–61. Available from: <http://dx.doi.org/10.3168/jds.2018-14772>.
33. Komarnytsky S, Rathinasabapathy T, Wagner C, Metzger B, Carlisle C, Panda C, et al. Endocannabinoid system and its regulation by polyunsaturated fatty acids and full spectrum hemp oils. *Int J Mol Sci*. 2021;22:1–16.
34. Nakajima Y, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, et al. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF- $\kappa$ B pathway inhibition. *FEBS Lett [Internet]*. 2006;580:613–9. Available from: <https://www.sciencedirect.com/science/article/pii/S0014579305015644>.
35. Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid influence on cytokine profile in multiple sclerosis. *Clin Exp Immunol [Internet]*. John Wiley & Sons, Ltd; 2005;140:580–5. Available from: <https://doi.org/10.1111/j.1365-2249.2005.02803.x>.
36. Murumalla R, Bencharif K, Gence L, Bhattacharya A, Tallet F, Gonthier M-P, et al. Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. *J Inflamm [Internet]*. 2011;8:33. Available from: <https://doi.org/10.1186/1476-9255-8-33>.
37. Matias I, Gonthier M-P, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and  $\beta$ -Pancreatic Cells and in Obesity and Hyperglycemia. *J Clin Endocrinol Metab*. 2006;91:3171–80.
38. Piomelli D. The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci England*. 2003;4:873–84.
39. Sidibeh CO, Pereira MJ, Lau Börjesson J, Kamble PG, Skrtic S, Katsogiannos P, et al. Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. *Endocrine*. 2017;55:839–52.
40. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. *FASEB J Off Publ Fed Am Soc Exp Biol United States*. 2005;19:1567–9.
41. Lowin T, Straub RH. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. *Arthritis Res Ther*. 2015;17:226.

42. Turcotte C, Blanchet M-R, Laviolette M, Flamand N. The CB(2) receptor and its role as a regulator of inflammation. *Cell Mol Life Sci* [Internet]. 2016/07/11. Springer International Publishing; 2016;73:4449–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/27402121>.
43. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. *Obes (Silver Spring) United States*. 2008;16:553–65.
44. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. *J Clin Endocrinol Metab United States*. 2007;92:4810–9.

## Figures





Figure 1


Adipose tissue relative protein abundance of ECS-related proteins of PP dairy cows supplemented with n-3 fatty acids.  $^+P \leq 0.10$ . Dairy cows were divided into two nutritional regiment groups from -21- 60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup>Cannabinoid receptor 2; <sup>3</sup>Monoglyceride Lipase; <sup>4</sup> $\beta$ -Actin which was used as reference protein. n=6 per treatment.



**Figure 2**

Liver tissue relative protein abundance of ECS- related protein and inflammatory protein of PP dairy cows supplemented with n-3 fatty acids.  $^+P=0.1$ . <sup>1</sup>Dairy cows were divided into two nutritional regiment groups from -21- 60 days PP; 1) Control group (CTL) - a standard Israeli diet, 2) FLX - a standard diet supplemented with flaxseed oil containing n-3. <sup>2</sup> Cannabinoid receptor 1; <sup>3</sup>Diacylglycerol Lipase Alpha;

<sup>4</sup>Monoglyceride Lipase; <sup>5</sup>Nuclear Factor Kappa-Light-Chain-Enhancer of activated B cells; <sup>6</sup> $\beta$ -Actin which was used as reference protein. n=5 per treatment.



**Figure 3**

Proposed model of effects of n-3 supplementation on the ECS in blood, liver and adipose tissue in peripartum dairy cows. n-3 supplementation reduces plasma AEA through reduced AA, this may result in reduction of CB1 receptor gene expression in WBCs and liver. In AT, the increased ChREBP and SREBP gene expression may lead to increased lipogenesis. Increased HSL and MGLL could result in the release of more FAs from the AT. These FAs can move to the liver and be converted to Diacylglycerols (DAGs) by Long-chain fatty acyl-CoA (LCFA-coA). In the liver, DAGs are converted to 2-AG by DAGLA. DAGs may activate through I $\kappa$ B kinase (IKK $\beta$ ) signaling pathway that can induce NF $\kappa$ B gene expression. The decrease in IL-6 gene expression may possibly lead to reduced inflammation and high regeneration of the liver. The Green color marks factors that has been increased while the Red marks factors that has been decreased. Genes are represented in italics.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfigandtables22.3.22.docx](#)